Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Becton Dickinson and Co (NYSE: BDX) shares are trading lower on Wednesday. The company announced an offering of $1.5 billion of common stock and $1.5 billion of Depositary shares representing interests in mandatory convertible preferred stock.

Why Becton Dickinson's Stock Is Trading Lower Today

FRANKLIN LAKES, N.J., May 19, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has commenced registered offerings of $1.5 billion of common stock, par value $1.00 per share, and $1.5 billion of depositary shares, each representing a 1/20th...

BD Announces Offerings of $1.5 billion of Common Stock and $1.5 billion of Depositary Shares Representing Interests in Mandatory Convertible Preferred Stock

Despite legal troubles with investors, Becton Dickinson has shown remarkable agility for its size with its COVID-19 testing program.

Is Becton Dickinson’s Investor Lawsuit Creating A Great Buying Opportunity?

Becton Dickinson & Co. BDX, +0.01% disclosed Wednesday it was offering the sale of $1.5 billion in 10-year and 30-year notes, as the medical technology company looks to repay $1 billion in debt due this year.

Becton Dickinson to issue $1.5 billion in 10-year, 30-year notes to payoff lower-rate debt due this year

Becton Dickinson and Company's (BDX) CEO Tom Polen on Q2 2020 Results - Earnings Call Transcript

Becton Dickinson's (BDX) second-quarter results reflect solid performance by the core Life Sciences and Interventional segments.

Becton Dickinson (BDX) Q2 Earnings and Revenues Top Estimates

AmerisourceBergen

Penumbra

Insulet

Medical Product companies have partially mitigated the impact of the pandemic with the massive adoption of COVID-19 related healthcare-support products and services.

Medical Products Stock Earnings on May 7: BDX, ABC & More

Becton, Dickinson's (BDX) fiscal second-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.

What's in Store for Becton, Dickinson's (BDX) Q2 Earnings?

Becton Dickinson, a maker of medical gear including coronavirus tests, is near a possible buy zone ahead of its next quarterly earnings report, slated for early May 7.
The post Top-Rated Becton Dickinson Near Buy Point After 2nd FDA Coronavirus Test Nod appeared first on Investor's Business Daily.

Top-Rated Becton Dickinson Near Buy Point After 2nd FDA Coronavirus Test Nod

Church & Dwight

Johnson & Johnson

Ventas

Walmart

The CARES Act will be great for healthcare and consumer stocks alike. These five stocks to buy could be the biggest winners.

5 Stocks to Buy For Big Gains On CARES Act Stimulus

Becton, Dickinson (BDX) receives EUA from the FDA for another molecular diagnostic test for COVID-19, which can return results in two to three hours.

BD (BDX) Receives EUA for New Coronavirus Detection Test

Abbott Labs

Hologic

Henry Schein

iShares U.S. Medical Devices ETF

iShares U.S. Healthcare ETF

QIAGEN

Thermo Fisher Scientific

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

It seems that testing for COVID-19 is the major key in controlling the outbreak and helps in making decisions like treatment protocols,  resource allocation and drafting the right healthcare policies.

Healthcare Stocks & ETFs to Gain on Coronavirus Test Progress

BD (BDX) partners with BioGX to introduce a new diagnostic test to help hospitals boost the capacity of quick, on-site testing of COVID-19.

BD Gets EUA for New Test to Combat the Coronavirus Crisis

Colgate-Palmolive

Clorox

Hormel Foods

In our search for the five safest dividend stocks around, we’ve looks for investments with a unique mix of characteristics, including being S&P 500 Dividend Aristocrats with 25+ years of consecutive dividend increases, notes income expert Ben Reynolds, a contributor to MoneyShow.com.

The 5 Safest Dividend Stocks In The S&P 500

Becton Dickinson and BioMedomics are the latest companies to launch a quick point-of-care SARS-CoV-2 diagnostic.

There's a New 15-Minute Coronavirus Test

Becton, Dickinson and Co. (NYSE: BDX), or BD, is officially throwing its hat in the ring to fight COVID-19.

What Becton Dickinson Brings to the Fight Against COVID-19

BD (BDX), along with BioMedomics, launches a new point-of-care test to help fight the coronavirus outbreak.

BD Launches New Test to Help Combat the Coronavirus Outbreak

AbbVie

Automatic Data Processing

Aflac

A. O. Smith

Cardinal Health

Chubb

Dover

Ecolab

Emerson Electric

General Dynamics

Genuine Parts

McDonald's

Medtronic

McCormick

Nucor

Walgreens

In times of market turmoil, one group of stocks that investors can count on to deliver reliable income growth is the Dividend Aristocrats: an elite group of companies that have produced at least 25 consecutive years of dividend hikes.

19 Dividend Aristocrats That Have Gone on Deep Discount

ABIOMED

Orthofix International

Amid the pandemonium on the account of coronavirus, we look into three stocks that have been struggling to cope with the scenario.

Coronavirus Hits Elective Procedures: 3 MedTech Stocks to Avoid

Ford Motor Company

Fiat Chrysler

General Motors

NuVasive

Royal Philips

ResMed

Smith & Nephew

Stryker

Tesla

Wright Medical Group

Zimmer Biomet Hlds

Some of the biggest medical device companies' stocks have dropped to attractive prices due to the current COVID-19 pandemic.

Can Medical Device Stocks Help Rebuild Your Portfolio?

Roche Holding AG

Teladoc

Amid the pandemonium associated with coronavirus, we look into four stocks that have the potential to benefit from this outbreak.

4 Potential Gainers Amid Intensifying Coronavirus Fears

BD (BDX) expects screening to ramp up by 1,000 per day once authorized.

BD (BDX) & BioGX Submit EUA to Speed Up Coronavirus Screening

Diagnostics giant Becton Dickinson said has submitted an emergency request to the U. S. Food and Drug Administration to increase capacity of tests for the has teamed with molecular diagnostics company BioGX and submitted "Emergency Use Authorization" requests to the Food and Drug Administration f.

Becton Dickinson Seeks Emergency FDA Request To Ramp Up Coronavirus Tests

News for Becton, Dickinson and Co. Stock (BDX)